2019 American Transplant Congress
Gut Microbiota May Affect a Variability of Tacrolimus Trough Levels in Kidney Transplant Recipients
*Purpose: The gut microbiota alters expression of drug-metabolizing enzymes and transporters, and consequently affects therapeutic dose and response of medicines. We aimed to investigate the…2019 American Transplant Congress
The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation
Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan
*Purpose: De novo DSA was demonstrated as a cause of chronic AMR, leading to worse graft survival. New strategies to treat chronic AMR have been…2019 American Transplant Congress
Prevalence of Non-Adherence to Immunosuppressive Medications in Kidney Transplant Recipients, Barriers and Predictors
*Purpose: Non-adherence to immunosuppressant therapy (IST) is one of the major factors leading to graft rejection. To our knowledge, limited data exist on the prevalence…2019 American Transplant Congress
Efficacy of Belatacept Conversion Protocols
Kaiser Los Angeles Medical Center, Los Angeles, CA
*Purpose: Belatacept (bela) is approved for de novo use in kidney transplantation. Conversion from CNI to bela is utilized for various reasons. Conversion is off-label…2019 American Transplant Congress
Tacrolimus Concentration/Dose Ratio is an Independent Predictor of Death-Censored Kidney Allograft Survival
*Purpose: Tacrolimus (Tac) remains the cornerstone of kidney transplantation immunosuppression. Its narrow therapeutic index demands therapeutic drug monitoring. The C/D ratio (Tac trough concentration /…2019 American Transplant Congress
Conversion from Tacrolimus Immediate Release to Tacrolimus Extended Release (Envarsus XR®): A Real World Cohort Highlighting Dosing Variability among Patients
*Purpose: Tacrolimus extended release (TacER) (Envarsus XR®) has become an attractive alternative to tacrolimus immediate release (TacIR) due to its once daily dosing scheme, favorable…2019 American Transplant Congress
Belatacept Conversion for Calcineurin Inhibitor-Associated Thrombotic Microangiopathy in Kidney Transplant Recipients
Nephrology Division, MGH, Boston, MA
*Purpose: Thrombotic Microangiopathy (TMA) in kidney transplant recipients is a serious complication that can cause graft loss. It can be associated with immunosuppressive medications such…2019 American Transplant Congress
Calcineurin Inhibitor Holiday for Management of Post Transplant Acute Kidney Injury
Nephrology, The Ottawa hospital, Ottawa, ON, Canada
*Purpose: Calcineurin inhibitors (CNI), despite dominating the armamentarium of post transplant medications, are associated with long term nephrotoxicity and also delayed recovery of renal function…2019 American Transplant Congress
Risk Factors for Initial Sub- and Supra-Therapeutic Tacrolimus Trough Levels in Renal Transplant Recipients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Sub-therapeutic tacrolimus trough levels have been associated with increased risk of rejection in renal transplant recipients and supra-therapeutic levels with infectious risks and drug…2019 American Transplant Congress
Monitoring And Management Of Proteinuria Is Often Ignored In Patients Receiving mTOR Therapy Following Orthotopic Liver Transplantation
*Purpose: Use of mTOR inhibitors, such as Everolimus (EVL), in liver transplant (LT) patients continues to rise as the side effect profile becomes more evident.…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 16
- Next Page »